Monday Aug 14, 2017
CD20 CAR T
Early phase IIa trial in 11 patients with refractory or relapsed B-cell lymphoma confirmed the feasibility and efficacy of anti-CD20 CAR-T cell therapy.
Monday Aug 14, 2017
Early phase IIa trial in 11 patients with refractory or relapsed B-cell lymphoma confirmed the feasibility and efficacy of anti-CD20 CAR-T cell therapy.
Comments (0)
To leave or reply to comments, please download free Podbean or
No Comments
To leave or reply to comments,
please download free Podbean App.